Revenue Growth: Increased 41.1% to $148.1 million from $105 million last year. Medical Market Sales: Increased 50.4% to $135.4 million. Other Markets Sales: Decreased 15% to $12.7 million from $15 million. Gross Margin: Slightly decreased to 28.5% from 28.6% in the first quarter of 2024. Operating Income: Increased 49.5% to $25.8 million. Effective Tax Rate: 15.3% for the first quarter of 2025. EPS: GAAP EPS increased 34.8% to $2.21; adjusted EPS increased 39.5% to $2.47. Adjusted EBITDA: Increased 45.9% to $30.2 million. Cash from Operations: Generated $13.8 million. Debt Reduction: Paid down approximately $7 million in debt. Leverage Ratio: Ended the quarter with a leverage ratio below 1.5 times. Capital Expenditures: $2.8 million.

Warning! GuruFocus has detected 3 Warning Signs with UFPT.

Release Date: May 06, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

UFP Technologies Inc (NASDAQ:UFPT) reported a strong first quarter with revenue growth of 41%, operating income increase of 45%, and EPS growth of 35% to $2.21. The medical business segment grew by 50%, driven by strong demand in the safe patient handling space, making it the second largest segment behind robotic surgery. Recent acquisitions have performed well, contributing significantly to growth, with organic growth at 2.3% and Medtech growth at 5.4%. UFP Technologies Inc (NASDAQ:UFPT) signed a key customer agreement in the safe patient handling space, providing exclusive manufacturing rights through mid-2030, supporting a large portion of the revenue acquired with the AJR business. The company is expanding its Dominican Republic operations, doubling the size of its facility in Santiago, which is a key competitive differentiator and an important component of its growth strategy.

Negative Points

The robotic surgery segment experienced a 6% decline in Q1 and is expected to have only modest growth in 2025 due to the completion of an inventory build by the largest customer in 2024. Gross margin slightly decreased to 28.5% from 28.6% in the first quarter of 2024, partly due to inefficiencies in the newly acquired AJR operations related to onboarding new direct labor associates. Advanced Components segment saw a 16.3% decline as resources were focused on faster-growing medtech opportunities. There is uncertainty regarding the impact of tariffs on demand from customers and potential inflationary effects on incoming raw materials. The company anticipates continued inefficiencies at AJR through the second quarter as it continues to onboard new associates.

Story Continues

Q & A Highlights

Q: Can you clarify the comments surrounding modest growth in the robotic surgery business through 2025? Is this for the business as a whole or just your largest customer? A: It's both. We have a forecast from our largest customer that slightly exceeds last year's low single-digit growth. For the robotic surgery as a whole, other platforms will contribute to growth, but it will still be low single digits. The decline in Q1 was partly due to large equipment sales last year, but unit sales are likely even or modestly growing.

Q: How should we think about your share at your largest robotic surgery customer going forward? A: Currently, we have about two-thirds of the share. Our largest customer does some manufacturing themselves, and another competitor has a small share. Over time, we've gained share, and our customer has brought on their own capacity to ensure a robust supply chain. We have a strong partnership, and they have assured us that they will always have a manual drape supplier, which makes us feel confident about our future with them.

Q: Are you seeing any pockets of excess inventory at any of your customers given the macro backdrop? A: We are not seeing excess inventory. The destocking that was holding us back in other markets seems to be behind us. Markets like infection prevention, interventional surgical, orthopedics, and wound care are growing nicely, indicating that business is back to usual.

Q: Can you discuss the growth in segments outside of robotics, such as interventional, surgical, infection prevention, ortho, and wound care? A: Infection prevention is growing due to new product developments, particularly around external catheters. Interventional and surgical segments are also seeing growth as destocking headwinds have subsided. Our acquisitions have contributed to this growth, and being part of UFP has accelerated their growth.

Q: How are tariffs impacting your competitive position, and are there any benefits? A: While there is no instant benefit from tariffs, we have won some business back from China, particularly in safe patient handling. We are well-positioned with two-thirds of our manufacturing and revenue in the US, which allows us to ramp up if needed.

Q: What are your capital allocation priorities, and are there any larger acquisitions on the horizon? A: We are focused on gaining more skills in injection molding and are looking at several smaller acquisitions. We have one large opportunity that is in early discussions, but most current talks are with smaller companies.

Q: Can you provide more details on the new product opportunities in robotic surgery? A: The new programs are up and running, so there won't be a long ramp-up period. They are expected to launch in the second half of the year, with meaningful revenue starting in 2026 and modest revenue this year.

Q: How do you view your long-term footprint in light of tariffs and reshoring discussions? A: We are committed to expanding in the Dominican Republic, as the savings far exceed the tariffs. We are also considering expansion in Asia Pacific to support customer needs, potentially through a joint venture.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments